Stocks · News reference
Japan’s Pharmaceuticals And Medical Devices Agency Issues Regulatory Approval To Natera's Signatera Test
This approval supports the use of the Signatera test to guide adjuvant atezolizumab (Tecentriq®) treatment decisions in patients with MIBC. Natera expects to commercially launch Signatera for MIBC in Japan in the first
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Live On CNBC, Kevin Simpson Announces Bought Natera
RBC Capital Maintains Outperform on Natera, Raises Price Target to $460
RBC Capital analyst Dan Leonard maintains Natera (NASDAQ:NTRA) with a Outperform and raises the price target from $350 to $460.
Natera shares are trading higher. The company announced that Japan's pharma and medical devices agency has approved its Signatera test as a companion diagnostic in muscle-invasive bladder cancer.